Interpace Diagnostics Announces Launch of New Thyroid Test

Interpace Diagnostics Group (NASDAQ:IDXG) a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests, bioinformatics, and pathology services for improved patient diagnosis and management, announced today that the Company will launch a proprietary new mutational panel for indeterminate thyroid nodules, ThyGeNEXT, at the upcoming American Association of Clinical Endocrinologists (AACE) Annual Meeting in Boston, MA, being held May 16-19^th.

As quoted in the press release:

ThyGeNEXT® includes numerous additional molecular markers, gene mutations, and RNA fusions compared to ThyGenX®. The new product represents a more comprehensive set of indicators to not only identity malignant or benign nodules, but also ascertain aggressiveness and other characteristics. “Molecular testing can play an important role in the overall assessment of patients with suspected thyroid cancer, and further advances in this area could provide new insights to better guide physician decision making,” stated Tom Fahey, M.D., Chief of Endocrine Surgery at New York Presbyterian Weill Cornell Medical Center and Professor of Surgery at Weill Cornell Medical College.

Importantly, the Company further noted that Novitas, its Medicare Administrative Carrier (MAC), has confirmed that ThyGeNEXT® will immediately be a covered service for Medicare beneficiaries.

Click here to read the full press release.